Daniel Klein

Summary

Affiliation: Kaiser Permanente
Country: USA

Publications

  1. ncbi request reprint Review of medical encounters in the 5 years before a diagnosis of HIV-1 infection: implications for early detection
    Daniel Klein
    Kaiser Permanente Medical Center, Hayward, California, USA
    J Acquir Immune Defic Syndr 32:143-52. 2003
  2. ncbi request reprint Cardiovascular Disease and HIV Infection
    Daniel Klein
    N Engl J Med 349:1869-70; author reply 1869-70. 2003
  3. ncbi request reprint Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?
    Daniel Klein
    Kaiser Permanente Medical Center, Hayward, California, USA
    J Acquir Immune Defic Syndr 30:471-7. 2002
  4. pmc Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy
    Chun Chao
    Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California 91101, USA
    AIDS 24:1765-70. 2010
  5. doi request reprint Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients
    Michael Horberg
    HIV Initiative, Kaiser Permanente, 2000 Broadway Oakland, CA 94612, USA
    J Acquir Immune Defic Syndr 53:62-9. 2010
  6. pmc HIV infection and the risk of cancers with and without a known infectious cause
    Michael J Silverberg
    Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA 94612, USA
    AIDS 23:2337-45. 2009
  7. doi request reprint Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study
    William Towner
    Department of Internal Medicine, Kaiser Permanente, Los Angeles, CA 90027, USA
    J Acquir Immune Defic Syndr 51:367-73. 2009
  8. ncbi request reprint Older age and the response to and tolerability of antiretroviral therapy
    Michael J Silverberg
    Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA 94612, USA
    Arch Intern Med 167:684-91. 2007
  9. doi request reprint Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients
    Michael Horberg
    HIV Initiative, Kaiser Permanente, Oakland, California 94612, USA
    HIV Clin Trials 9:367-74. 2008
  10. doi request reprint Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons
    Chun Chao
    Kaiser Permanente Southern California, Pasadena, CA, USA
    AIDS 26:2223-31. 2012

Collaborators

Detail Information

Publications17

  1. ncbi request reprint Review of medical encounters in the 5 years before a diagnosis of HIV-1 infection: implications for early detection
    Daniel Klein
    Kaiser Permanente Medical Center, Hayward, California, USA
    J Acquir Immune Defic Syndr 32:143-52. 2003
    ..In our setting, effective risk assessment before symptoms arise offers greater potential for raising the mean CD4 cell count at diagnosis than does increased awareness of selected HIV-associated clinical prompts...
  2. ncbi request reprint Cardiovascular Disease and HIV Infection
    Daniel Klein
    N Engl J Med 349:1869-70; author reply 1869-70. 2003
  3. ncbi request reprint Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?
    Daniel Klein
    Kaiser Permanente Medical Center, Hayward, California, USA
    J Acquir Immune Defic Syndr 30:471-7. 2002
    ..Other HIV-related mechanisms may be at work, causing increased CHD and MI risk among all HIV-infected persons...
  4. pmc Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy
    Chun Chao
    Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California 91101, USA
    AIDS 24:1765-70. 2010
    ..uninfected patients from the same integrated healthcare system, and to identify prognostic factors for HIV-related NHL in the era of combined antiretroviral therapy...
  5. doi request reprint Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients
    Michael Horberg
    HIV Initiative, Kaiser Permanente, 2000 Broadway Oakland, CA 94612, USA
    J Acquir Immune Defic Syndr 53:62-9. 2010
    ..To better characterize the long-term effects of tenofovir on renal function in a large managed care organization...
  6. pmc HIV infection and the risk of cancers with and without a known infectious cause
    Michael J Silverberg
    Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA 94612, USA
    AIDS 23:2337-45. 2009
    ..To evaluate the risk of cancers with and without a known infectious cause in HIV-infected persons...
  7. doi request reprint Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study
    William Towner
    Department of Internal Medicine, Kaiser Permanente, Los Angeles, CA 90027, USA
    J Acquir Immune Defic Syndr 51:367-73. 2009
    ..To determine the safety and efficacy of changing enfuvirtide to raltegravir in HIV-1-infected patients with HIV-1 RNA below the level of quantification for at least 6 months on an enfuvirtide-containing antiretroviral regimen...
  8. ncbi request reprint Older age and the response to and tolerability of antiretroviral therapy
    Michael J Silverberg
    Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA 94612, USA
    Arch Intern Med 167:684-91. 2007
    ..The unique health needs of a growing older adult population infected with human immunodeficiency virus (HIV) require study, especially in terms of the response to and tolerability of highly active antiretroviral therapy (HAART)...
  9. doi request reprint Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients
    Michael Horberg
    HIV Initiative, Kaiser Permanente, Oakland, California 94612, USA
    HIV Clin Trials 9:367-74. 2008
    ..Evaluate responses and safety of ritonavir-boosted atazanavir ("boosted atazanavir") compared to unboosted atazanavir among antiretroviral-naïve patients in the clinical managed care setting...
  10. doi request reprint Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons
    Chun Chao
    Kaiser Permanente Southern California, Pasadena, CA, USA
    AIDS 26:2223-31. 2012
    ..Studies are needed to directly evaluate the effect of ART use on cancer risk...
  11. ncbi request reprint Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection
    Michael J Silverberg
    Kaiser Permanente Northern California, Oakland, California, USA
    Ann Intern Med 150:301-13. 2009
    ..Antiretroviral agents, particularly protease inhibitors (PIs), may adversely affect lipid levels in patients with HIV infection. However, it is not known whether HIV-associated dyslipidemia is more difficult to treat...
  12. doi request reprint HIV quality performance measures in a large integrated health care system
    Michael Horberg
    HIV Initiative, Kaiser Permanente, Oakland, California, USA
    AIDS Patient Care STDS 25:21-8. 2011
    ..S. rate. These results have implications for improving our care process going forward, as well as for the new U.S. domestic HIV/AIDS Strategy...
  13. doi request reprint Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy
    Judith S Currier
    Circulation 118:e29-35. 2008
  14. pmc HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL
    Yumi Mitsuya
    Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford 94305, and Kaiser Permanente Medical Care Program Northern California, Oakland, CA, USA
    J Acquir Immune Defic Syndr 43:56-9. 2006
    ..Genotype validity was confirmed in 49 of 50 patients with a previous or follow-up genotype. The belief that genotypic resistance testing is unreliable in samples with low-level viremia should be reassessed...
  15. pmc HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance
    Soo Yon Rhee
    Division of Infectious Diseases, Department of Medicine, Stanford University, CA 94301, USA
    J Infect Dis 192:456-65. 2005
    ..In contrast, nonpolymorphic treatment-associated mutations may be more sensitive and specific markers of transmitted HIV-1 drug resistance...
  16. pmc Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations
    Yumi Mitsuya
    Department of Medicine, Division of Infectious Diseases, Stanford University Medical Center, Stanford, California 94305, USA
    J Virol 82:10747-55. 2008
    ....
  17. ncbi request reprint Perceptions of human immunodeficiency virus testing services among HIV-positive persons not in medical care
    Michael Horberg
    Sex Transm Dis 33:464; author reply 465. 2006